MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A phase 1 randomised, placebo-controlled, single-blind study to characterise the biomarker
effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive
impairment. A maximum of 54 participants will be recruited to the two part study. The first
part of the study will identify whether it is possible to identify biomarkers that may be
used in future studies with JNJ-40346527 and part 2 will investigate a minimal efficacious
JNJ-40346527 dose.